EsoCheck/EsoGuard在食管裂孔疝修补术前筛查Barrett食管的初步研究
这项前瞻性横断面研究在计划行食管裂孔疝修补术的胃食管反流病患者中,比较术中EsoCheck/EsoGuard与内镜活检筛查Barrett食管的表现。28例患者中EsoGuard敏感性83.3%、特异性63.6%,阴性预测值93.3%。阳性结果需内镜确诊,采样无并发症。
要点
- EsoGuard筛查Barrett食管敏感性83.3%,阴性预测值93.3%。
- 特异性63.6%,假阳性者中5例病理示慢性炎症改变。
- EsoCheck术中采样安全,未发生相关并发症。
核心结论
- EsoCheck/EsoGuard敏感性高,符合Barrett食管筛查工具标准,但特异性低,阳性结果须行内镜活检确诊。
研究设计与样本
- 单中心前瞻性横断面初步研究,纳入18岁以上、有胃食管反流病诊断并计划行食管裂孔疝修补术的患者,全麻下采集远端食管样本。
- 共28例患者完成EsoCheck采样和疝修补术,平均年龄56.9±14.9岁,平均BMI 28.6±6.2。
主要发现
- 28例中检出Barrett食管6例(21%),其中3例为短段Barrett食管(<3 cm)。
- EsoGuard敏感性83.3%(95%CI 35.9-99.6),特异性63.6%(95%CI 40.7-82.8)。
- 阳性预测值38.5%(95%CI 24.4-54.7),阴性预测值93.3%(95%CI 69.5-98.9)。
- 8例EsoGuard假阳性中5例病理示慢性炎症性黏膜改变。
- EsoCheck采样未发生相关并发症。
临床怎么用
- 在食管裂孔疝修补术前可考虑使用EsoCheck/EsoGuard进行Barrett食管筛查,阴性结果有助于排除。
- EsoGuard阳性结果不能直接诊断Barrett食管,须行上消化道内镜活检确认。
局限性
- 本研究为单中心初步研究,样本量仅28例,敏感性95%CI较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Esophageal adenocarcinoma (EAC) has poor survival outcomes, yet population-level screening remains limited. EsoCheck, a swallowable balloon device paired with the EsoGuard DNA methylation assay, is a minimally invasive screening tool for Barrett's esophagus (BE), a precursor to EAC. Hiatal hernia is a strong risk factor for BE. This pilot study provides preliminary insight into the diagnostic performance of intraoperative EsoCheck/EsoGuard compared with upper endoscopic biopsies for screening patients undergoing hiatal hernia repair. METHODS: This prospective cross-sectional study was conducted at a single institution. Eligible participants were aged ≥ 18, had a diagnosis of GERD, and were undergoing BE screening or surveillance followed by planned hiatal hernia repair. Exclusion criteria included a history of esophageal malignancy or surgery. Patients were placed under general anesthesia for sample collection, followed by hiatal hernia repair. Distal esophageal samples collected via EsoCheck and upper endoscopy were analyzed by the EsoGuard assay and histopathology, respectively. RESULTS: 28 patients underwent successful sample collection and hernia repair. Mean BMI was 28.6 ± 6.2 and mean age was 56.9 ± 14.9 years. Patients were 71% women, 79% White, 36% obese, and 39% had a history of smoking. Mean number of risk factors per patient based on ACG guidelines was 3.5 ± 1.1. BE was detected in 6 (21%) patients, with 3 being short-segment BE (< 3 cm). EsoGuard showed sensitivity of 83.3% (95% CI 35.9-99.6) and specificity of 63.6% (95% CI 40.7-82.8). Positive predictive value was 38.5% (95% CI 24.4-54.7) and negative predictive value was 93.3% (95% CI 69.5-98.9). Of the 8 patients with false-positive EsoGuard results, 5 had chronic inflammatory mucosal changes on pathology. No complications were associated with EsoCheck sampling. CONCLUSIONS: EsoCheck/EsoGuard demonstrates high sensitivity and meets the criteria for a screening tool for BE. Given its low specificity, positive results mandate a confirmatory test, such as upper endoscopy with biopsies.
引用
- Ho WLJ, Liang Y, Penny P, et al. Pilot study of EsoCheck/EsoGuard for detecting Barrett's esophagus in high-risk patients undergoing hiatal hernia repair. Surg Endosc. 2026. PMID: 42377511. doi:10.1007/s00464-026-12685-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。